Surprising new documentary explores emerging Texas mega-metro that could rival Houston

bigger in texas

San Antonio, Austin, and the space in between could be the state's next big mega-metro. Photo by Matthew LeJune on Unsplash

It's no secret that Austin and San Antonio are becoming some of the biggest cities in Texas, and that together, they just might rival the likes of Houston and Dallas-Fort Worth one day.

A new documentary called San Antonio-Austin: The Emerging Mega-Metro takes a deep dive into the booming 80-mile region between the Central Texas cities

Produced by KLRN, San Antonio's local PBS station, the program centers on the region's growth and the challenges that arise with such rapid expansion, such as water scarcity, environmental impacts, and increasingly common transportation and traffic woes.

They're issues that Houston residents know well, as the city's population continues to explode at a staggering rate.

"We know the area between San Antonio and Austin is growing at a tremendously rapid pace, but what is really happening is the development of a mega-metro that will be one of the biggest economic powerhouses in the world," says Shari St. Clair, the documentary's executive producer, in a release.

“We delve into the questions that need to be asked right now — how do we retain quality of life as we grow? How do we build a sustainable workforce?" St. Clair continues. "And, can San Antonio and Austin truly join forces and work together to make the most of this incredible opportunity?"

The hour-long documentary is hosted by former San Antonio mayor Henry Cisneros, who also authored The Texas Triangle: An Emerging Power in the Global Economy. The special highlights several prominent Central Texas leaders, including interviews with Austin Mayor Kirk Watson, San Antonio Mayor Ron Nirenburg, U.S. Congressman Greg Casar, and more.

As Texas is also a state of committed sports fans, the idea of a mega-metro between Austin and San Antonio is additionally explored through a sports lens. The documentary interviewed legends like Nolan Ryan, Sean Elliot, and Spurs Chairman Peter J. Holt.

San Antonio-Austin: The Emerging Mega-Metro can be watched online at klrn.org.

------

This article originally ran on CultureMap.

From Your Site Articles
Texas Central Partners hopes to partner with Amtrak on high-speed trains in Texas. Rendering courtesy of Texas Central

Houston-Dallas high-speed bullet train gets back on the rails thanks to potential Amtrak partnership

speeding back

In the latest chapter in the saga of the high-speed bullet train between Houston and Dallas, Amtrak is now involved.

According to a press release, Texas Central Partners and Amtrak are exploring a partnership to work together on the proposed Dallas-Houston high-speed rail project that's been under consideration for more than a decade.

Amtrak has cooperated with Texas Central on various initiatives since 2016 and the two entities are now evaluating a potential partnership to determine the line's viability.

“If we are going to add more high-speed rail to this country, the Dallas to Houston Corridor is a compelling proposition and offers great potential,” says Amtrak senior VP of High-Speed Rail Development Programs Andy Byford. “We believe many of the country's biggest and fastest-growing metropolitan areas, like Houston and Dallas, deserve more high quality high-speed, intercity rail service, and we are proud to bring our experience to evaluate this potential project and explore opportunities with Texas Central so the state can meet its full transportation needs.”

The route being proposed would span approximately 240 miles, going at 250 mph, resulting in a trip that would take less than 90 minutes between the two cities.

Texas Central has been working towards getting a train rolling since 2013, including lining up a potential builder in 2021. But the project has had pushback from Texas politicians and landowners along the route; a lawsuit against the project was filed by six rural counties in 2021, and the Texas Legislature passed a law prohibiting the state from spending any funds on the project.

Facing a seeming dead end, Texas Central CEO Carlos Aguilar and its board members resigned in June 2022; Michael Bui, a consultant, has been serving as CEO since then.

Texas Central and Amtrak have submitted applications to several federal programs in connection with further study and design work, including the Consolidated Rail Infrastructure Safety and Improvements (CRISI) grant program, the Corridor Identification and Development program, and the Federal-State Partnership for Intercity Passenger Rail (FSP-National) grant program.

Amtrak previously entered into an agreement with Texas Central to provide through-ticketing using the Amtrak reservation system and other support services for the planned high-speed rail line.

"This high-speed train, using advanced, proven Shinkansen technology, has the opportunity to revolutionize rail travel in the southern U.S., and we believe Amtrak could be the perfect partner to help us achieve that,” says Bui in a statement.

Despite its detractors, the project is forecast to provide social, environmental, employment and economic benefits including reducing greenhouse gas emissions by more than 100,000 tons per year, saving 65 million gallons of fuel and removing 12,500 cars per day from I-45.

The release from Amtrak has statements from both Dallas Mayor Eric L. Johnson and Houston Mayor Sylvester Turner, who calls the collaboration between Texas Central and Amtrak "an important milestone for the City of Houston and this project."

Byford joined Amtrak in April 2023 to begin developing a team focused on high-speed opportunities throughout the U.S. In his newly created role, he will develop and lead the execution of Amtrak’s long-term strategy for high-speed rail throughout the country, including the extension of the Crescent from Mississippi through Louisiana and Texas; Kansas DOT’s Heartland Flyer Extension Corridor Identification and Development (Corridor ID) connecting Wichita to Oklahoma and Texas, and TxDOT’s applications for the Texas Triangle (Houston — Dallas – Fort Worth – San Antonio) routes.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings